3 results
Approved WMOCompleted
To measure in vivo biodistribution of 89Zirconium labeled GSK2849330 and characterize its dose receptor occupancy relationship in subjects with advanced HER3 positive solid malignancies.
Approved WMORecruiting
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…
Approved WMOCompleted
Primary:• To compare the efficacy of zanubrutinib (also known as BGB-3111) versus ibrutinib as measured by overall response rate determined by investigator assessment Secondary:• To compare the efficacy of zanubrutinib versus ibrutinib as measured…